Vaccine composition comprising interleukin-15 (IL-15)

Details Vaccine composition comprising interleukin-15 (IL-15) Vaccine composition comprising interleukin-15 (IL-15)

2011-08-30

2011-08-30

Seidel, Marianne C (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S351000

Reexamination Certificate

active

08007776

ABSTRACT:
Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host.IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide.Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.

REFERENCES:
patent: 5894018 (1999-04-01), Davila et al.
patent: 6013480 (2000-01-01), Grabstein et al.
patent: 6344192 (2002-02-01), Grooten et al.
patent: WO 95/27722 (1995-10-01), None
patent: 00 02582 (2000-01-01), None
Gonzalez S. et al. P64k meningococcal protein as immunological carrier for wek immunogens. Scand. J. Immunol. 2000. vol. 52, p. 113-116.
Schwartz RH and Mueller DL. Immunological Tolerance. In Fundamental Immunology, 5th Edition. 2003. W.E. Paul (Ed)., Lippincott, Williams, and Wilkins.
Al-Mughales J, et al. The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin. Exp. Immunol. 1996. vol. 106, pp. 230-236.
Obermeier F, et al. IL-15 protects intestinal epithelial cells. Eur. J. Immunol. 2006. vol. 36, pp. 2691-2699.
Kukita T, et al. Autocrine and/or paracrine growth of adult T-cell leukemia tumour cells by interleukin 15. Br. J. Haematol. 2002. vol. 119, pp. 467-474.
Brewer JM, et al. Aluminum hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 1999. vol. 163, pp. 6448-6454.
Fehniger Todd A, et al., “Interleukin 15: biology and relevance to human disease”,Blood2001, 97: 14-32.

Affiliated with

Also associated with

Rating

Vaccine composition comprising interleukin-15 (IL-15) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine composition comprising interleukin-15 (IL-15), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine composition comprising interleukin-15 (IL-15) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2647043